Treatment of Migraine Headaches with Sumatriptan in Pregnancy
| Autor: | Samantha F. Eichner, L Brian Cross, Michelle L. Hilaire |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Pediatrics
medicine.medical_specialty Migraine Disorders Pregnancy Complications Cardiovascular Population law.invention Randomized controlled trial Pregnancy Risk Factors law medicine Humans Pharmacology (medical) Prospective cohort study education Clinical Trials as Topic education.field_of_study Sumatriptan business.industry Incidence (epidemiology) Pregnancy Outcome Abnormalities Drug-Induced medicine.disease Serotonin Receptor Agonists Migraine Anesthesia Female Headaches medicine.symptom business medicine.drug |
| Zdroj: | Annals of Pharmacotherapy. 38:1726-1730 |
| ISSN: | 1542-6270 1060-0280 |
| DOI: | 10.1345/aph.1d586 |
| Popis: | OBJECTIVE To review the literature for treatment of migraine headaches with sumatriptan during pregnancy. DATA SOURCES Studies and reports were located in International Pharmaceutical Abstracts (1970-September 2003) and MEDLINE (1966-week 3 September 2003). DATA SYNTHESIS Research has been performed to evaluate the risk of teratogenesis after sumatriptan exposure in pregnant patients. Data have been collected in areas including placental transmission of sumatriptan, prospective pregnancy registries, open-labeled and controlled prospective studies, and a retrospective prescription-linked study. As of August 6, 2004, no randomized controlled trials have been conducted with exposure to sumatriptan during pregnancy. CONCLUSIONS Teratogenesis occurs in approximately 150 000 births per year which represents an incidence of 3–5%. Available literature to date indicates that exposure to sumatriptan during pregnancy has no additional risk of birth defects compared with the incidence in the general population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|